San Diego, CA (PRWEB) June 02, 2012
NexDx, Inc., a science-driven molecular diagnostics company founded less than one year ago, is one of San Diego’s 30 “Cool Companies” for 2012, according to the San Diego Venture Group (SDVG).
SDVG, which sponsors the annual “Cool Companies” competition, selected this year’s winners from a field of over 150 entrants in the life sciences and technology fields on the basis of investor appeal, progress and innovation. The 30 “Cool Companies” are listed at: http://www.sdvg.org/thecool
“We are honored by the San Diego Venture Group’s recognition of NexDx and will continue our exciting work of exploring new ways to improve the quality of biomarkers and tests for rheumatologists and patients, and novel autoimmune disease targets and companion diagnostics for biopharmaceutical companies,” said Jonathan Lim, M.D., NexDx’s Chairman, CEO and Co-Founder. Dr. Lim is the former President, CEO and Board Director of Halozyme Therapeutics, Inc.
NexDx scientists use extremely “cool” technologies in their research to develop and commercialize a reliable, low-cost test to diagnose rheumatoid arthritis (RA) long before symptoms become severe and when early therapy for this potentially crippling auto-immune disease might be the most effective. These technologies include a proprietary bioinformatics platform that identifies novel biological trends on a global scale, as well as genome-wide analyses of epigenetic signatures for innovative diagnostics and therapeutics.
Currently, most people with RA are diagnosed after the debilitating disease is already well established and has progressed. RA disease progression is characterized by swollen joints and crippling stiffness, particularly of the hands and feet. RA can also damage the heart and lungs and can lead to accelerated atherosclerosis.
“With early diagnosis, physicians might be able to aggressively treat rheumatoid arthritis earlier than now possible and personalize therapy to minimize or halt disease progression,” said Gary Firestein, M.D., an internationally recognized rheumatologist as well as NexDx’s Scientific Advisor and Co-Founder. Dr. Firestein is Dean and Associate Vice Chancellor of Translational Medicine at UC San Diego.
NexDx’s research program is fueled by Dr. Firestein’s discoveries in epigenetics, which refers to the modifications to DNA that influence the expression, or activity, of an individual’s genes. These reversible modifications play an important role in determining disease susceptibility and severity, as well as response to therapeutic drugs.
NexDx and the other “Cool Companies” will be showcased at SDVG’s 10th Annual Venture Summit, June 6, 2012. According to SDVG, over 100 venture capitalists and 500 life sciences and technology professionals are expected to attend.
“We’ve got a wide range of industries represented with this year’s selection, including five in clean tech, eleven in high tech and nine in life sciences,” said SDVG President David Titus. “Last year we were standing room only for the summit, and we expect the same this year.”
NexDx, Inc., located in Sorrento Valley, is a science-driven molecular diagnostics company providing next generation products and services for personalized medicine in rheumatoid arthritis and other autoimmune diseases.
The company, founded in August 2011 by Jonathan E. Lim, M.D. and Gary S. Firestein, M.D., is a pioneer in the application of epigenomics and other next generation molecular approaches to the discovery, development, and commercialization of novel biomarkers and tests for diagnostic and therapeutic applications in autoimmune diseases.
SAN DIEGO VENTURE GROUP
The San Diego Venture Group is a non-profit business association whose mission is to provide an informal atmosphere that fosters ideas about how to form, fund and build new ventures.
With over 800 affiliated members and an average monthly meeting attendance of 325 people, SDVG helps San Diego become a significant entrepreneurial and venture center.